A common type of bacteria found in our guts could contribute to bowel cancer, according to new research.
An international team of scientists, including Dr Henry Wood and Professor Philip Quirke from the School of Medicine at the University of Leeds, have shown that a toxin called colibactin released by a strain of E. coli causes unique patterns, or fingerprints, of DNA damage to the cells lining the gut.
The fingerprints were also seen in bowel cancer tumours, showing for the first time a direct link between the bacterial toxin and the genetic changes that drive cancer development.
The team suggests that detecting this specific DNA damage in the cells lining the gut could one day allow doctors to identify people at higher risk of the disease and become used alongside current bowel cancer screening tests.
Other bacterial toxins from gut bacteria might have similar effects and the hunt for them is now on as researchers seek to determine whether this mechanism of DNA damage is widespread.
This research was funded by Cancer Research UK as part of a £20 million Cancer Research UK Grand Challenge award, with sequencing data provided by Genomics England, and is published in Nature today.
There are around 42,000 new bowel cancer cases in the UK every year, where it remains the second most common cause of cancer death. Understanding the early triggers that could lead to bowel cancer may help doctors prevent its development and detect it at its earliest stage, when treatment is most likely to be successful.
This has led scientists to investigate the role that the microbiome trillions of bacteria, viruses, fungi and other single-celled organisms plays in the development of bowel cancer.
Professor Philip Quirke, Grand Challenge co-investigator at the University of Leeds, said: Our goal is to understand the causes of bowel cancer, so discovering the role of colibactin represents an important step. As a Grand Challenge team, we are now looking at other bacteria and their toxins associated with bowel cancer, and we hope to identify more DNA damage fingerprints to paint a better picture of risk factors.
We will then need to work out how we can reduce the presence of high-risk bacteria in the gut. But this is all in the future, so for now people should continue to eat a healthy diet and participate in bowel cancer screening.
This discovery of a direct link between a bacterium and bowel cancer tumours is the first outcome of a £20 million international Grand Challenge project with Hubrecht Institute in The Netherlands, striving to understand how the microbiome impacts on cancer risk, development and treatment.
Illustration of mutation identification in colorectal tumor. Profile of bacterial footprint is shown at the top right, specific mutations are highlighted as red spheres in the DNA molecule. Credit: DEMCON | nymus3D, ©Hubrecht Institute.
John Barnes, patient advocate for Grand Challenge said: As a cancer survivor, I dont want others to go through what Ive gone through. Catching bowel cancer at an earlier stage while its still treatable has the potential to save thousands of peoples lives. This brilliant research gives me hope that people may not have to suffer from bowel cancer in the future.
Nicola Smith, senior health information manager at Cancer Research UK, said: The more doctors understand about how bowel cancer develops, the better they will be at detecting it and helping people reduce their risk.
But there are already things that people can do right now to help reduce their risk of bowel cancer. Not smoking, keeping a healthy weight, eating a diet high in fibre and low in red and processed meat will all help. And for those who are eligible, participating in bowel screening can help to detect the disease at an early stage.
Commenting on the findings, Professor Sir Mark Caulfield FMedSci, Chief Scientist at Genomics England, said: Genomics England are delighted that data provided to us by our participants has enabled researchers to help accelerate these findings, which are a world-first. Without their participation and generosity this outcome would not have been achievable.
There are around 42,000 new bowel cancer cases in the UK every year, and it remains the second most common cause of cancer death. This research opens a new vista on the biology of colon cancer and has significantly improving our understanding of how this type of cancer develops. We are very optimistic that this research will ultimately lead to improved diagnoses and better outcomes for patients.
Our participants, who contribute to the continual growth of our research environment and the quality of the data within it, are critical in facilitating genomic research that leads to clinical insights like these.
Tracing the toxic fingerprints
Researchers at the Hubrecht Institute led by Professor Hans Clevers focused on one strain of E. coli producing a toxin called colibactin, and which is more often present in the stool samples of people with bowel cancer compared to healthy people.
Because colibactin can cause DNA damage in cells grown in the lab, they thought the toxin might be doing the same to cells lining the gut.
The team used human intestinal organoids, miniature replicas of the gut grown in the lab, and exposed them to colibactin-producing E. coli. They analysed the DNA sequence of the gut cells in the organoids after 5 months and found about double the DNA damage in them, compared to organoids exposed to regular E. coli that didnt produce the colibactin.
The researchers also found that the DNA damage caused by colibactin followed two very specific patterns like a fingerprint which were unique to the toxin.
To determine whether the DNA damage caused by the bacterium played a role in bowel cancer, the researchers then analysed the DNA sequences of more than 5500 tumour samples from the UK and Netherlands, with the help of Dr Henry Wood and Professor Quirke.
First, they checked for the two colibactin DNA damage fingerprints in over 3600 Dutch samples of various cancer types. The fingerprints were present in several types of tumour, but much more often in bowel cancers than other cancer types.
The researchers then refined their investigation on bowel cancer tumours specifically, and analysed over 2000 bowel cancer samples from the UK, collected as part of the 100,000 Genomes Project run by Genomics England.
Among these samples, the colibactin fingerprints were present in 4-5% of patients. This suggests that colibactin-producing E. coli may contribute to 1 in 20 bowel cancer cases in the UK. It will be up to further studies to shed light on just how much of a role the toxin could play in these cases, and what other components of the microbiome may be involved in the early stages of bowel cancer.
Professor Hans Clevers, Grand Challenge co-investigator at the Hubrecht Institute, said: Things like tobacco or UV light are known to cause specific patterns of DNA damage, and these fingerprints can tell us a lot about past exposures that may have caused cancer to start. But this is the first time weve seen such a distinctive pattern of DNA damage in bowel cancer, which has been caused by a bacterium that lives in our gut.
Further down the line, the researchers say that looking for DNA damage fingerprints like the ones associated with colibactin in the cells of the gut lining could be used to identify those who are at a greater risk of developing the disease.
Top image: Illustration of colibactin binding to specific DNA sequence. Credit: DEMCON | nymus3D, ©Hubrecht Institute.
For University of Leeds media enquiries contact press officer Simon Moore on +44 (0)113 34 38059 or email@example.com
For Cancer Research UK media enquiries contact Daimona Kounde in the Cancer Research UK press office on 020 3469 5128 and Daimona.Kounde@cancer.org.uk or, out of hours, on 07050 264 059.
The paper 'A mutational signature in human colorectal cancer induced by genotoxic pks+ E. coli' is published in Nature on 27 February 2020 and is online here: https://www.nature.com/articles/s41586-020-2080-8